May 26, 2017
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Eleven Biotherapeutics reports $6.1 million loss in first quarter
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Eleven Biotherapeutics reported a net loss of $6.1 million, or $0.25 per share, in the first quarter of 2017 compared with a net loss of $7.6 million, or $0.39 per share, in the same period of 2016.
The company had revenues of $0.4 million in the first quarter compared with $0.2 million last year, according to a press release.
Research and development costs were $2.9 million in the quarter compared with $4.6 million in 2016’s first quarter. The decrease was attributed to lower drug development expenses.
Cash and cash equivalents totaled $20.3 million as of March 31 compared with $25.3 million as of Dec. 31, 2016.